Edgemont Partners Company Profile

Background

Edgemont Partners, established in 2001, is a premier healthcare investment bank dedicated exclusively to providing merger and acquisition (M&A) advisory and growth capital raising services to healthcare companies. With a mission to deliver unparalleled strategic advice and transaction execution, Edgemont has become a significant player in the healthcare investment banking sector. The firm's vision centers on leveraging deep domain expertise and a principled approach to achieve optimal outcomes for its clients. Over the years, Edgemont has successfully closed over 200 transactions, cumulatively exceeding $90 billion in total transaction value.

Key Strategic Focus

Edgemont's strategic focus is centered on providing specialized M&A advisory and growth capital raising services exclusively within the healthcare sector. The firm emphasizes deep domain expertise, exceptional execution, and a conflict-free approach to deliver optimal outcomes for its clients. Edgemont's core objectives include:

Specialization in Healthcare M&A: Focusing solely on healthcare allows Edgemont to understand the intricacies of its clients' businesses and the mindset of potential transaction partners.

Tailored Approach: Recognizing that no two companies or transactions are the same, Edgemont delivers customized strategies tailored to each client's unique needs.

Integrity and Quality: Maintaining the highest standards of integrity and quality in all aspects of its services, ensuring that clients' best interests are always prioritized.

The firm targets various segments within the healthcare industry, including pharmaceuticals, medical devices, healthcare services, and life sciences, aiming to provide strategic advice and transaction execution that maximize value for its clients.

Financials and Funding

As a privately held investment bank, Edgemont Partners does not publicly disclose detailed financial information. However, the firm's significant transaction volume and aggregate transaction value exceeding $90 billion indicate a robust financial standing and a strong position within the healthcare investment banking sector.

Pipeline Development

Edgemont Partners' pipeline development is characterized by a consistent flow of high-profile transactions across various healthcare sectors. The firm's recent activities include:

Sale of Precision Healthcare to IVX Health: In October 2020, Edgemont acted as the exclusive financial advisor in the sale of Precision Healthcare, a leading provider of infusion and injection therapy, to IVX Health.

Sale of Michigan Institute of Urology to Solaris Health: In November 2021, Edgemont advised the Michigan Institute of Urology on its sale to Solaris Health, expanding Solaris' network to over 330 providers across multiple states.

Merger of West Dermatology with Platinum Dermatology Partners: In June 2022, Edgemont advised West Dermatology on its merger with Platinum Dermatology Partners, creating a leading dermatology group with over 100 locations in the Southwestern U.S. and Southern California.

These transactions reflect Edgemont's active role in facilitating significant deals within the healthcare industry.

Technological Platform and Innovation

Edgemont Partners distinguishes itself through its deep domain expertise and a principled, conflict-free approach to investment banking. While the firm does not publicly disclose proprietary technologies or specific scientific methodologies, its success is attributed to:

Specialized Knowledge: Focusing exclusively on healthcare M&A allows Edgemont to possess an in-depth understanding of the industry, enabling the firm to identify unique opportunities and deliver tailored solutions.

Superior Execution: Leveraging bulge bracket training and proven transaction experience, Edgemont ensures meticulous execution of complex transactions.

Integrity and Quality: Maintaining the highest standards of integrity and quality in all aspects of its services, ensuring that clients' best interests are always prioritized.

These factors collectively contribute to Edgemont's reputation as a trusted advisor in the healthcare investment banking sector.

Leadership Team

Edgemont Partners' leadership team comprises seasoned professionals with extensive experience in healthcare investment banking. Key members include:

David Blume: Managing Director and Co-Founder, with a background in investment banking and a focus on healthcare M&A.

Jeff Swearingen: Co-Founder and Managing Director, specializing in corporate development and healthcare financial services.

Eugene Goldenberg: Managing Director, leading the firm's investment banking franchise in post-acute services, distribution, and staffing.

Patrick Bradley: Managing Director, with expertise in investment banking, mergers and acquisitions, and private equity.

Brett Skolnik: Managing Director, focusing on healthcare investment banking and biotechnology.

These leaders bring a wealth of experience and strategic insight, driving Edgemont's success in the healthcare investment banking sector.

Leadership Changes

In January 2020, Edgemont Partners appointed Eugene Goldenberg as Managing Director to lead its investment banking franchise in post-acute services, distribution, and staffing. Mr. Goldenberg brought over 15 years of experience advising public and private companies in various transactions, enhancing Edgemont's capabilities in these sectors.

Competitor Profile

Market Insights and Dynamics

The healthcare investment banking sector is characterized by a competitive landscape with several firms specializing in M&A advisory and capital raising services. The market is driven by factors such as technological advancements, regulatory changes, and the ongoing consolidation within the healthcare industry.